Fallopian Tube Carcinoma
61
10
18
26
Key Insights
Highlights
Success Rate
81% trial completion
Published Results
14 trials with published results (23%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
9.8%
6 terminated out of 61 trials
81.3%
-5.3% vs benchmark
7%
4 trials in Phase 3/4
54%
14 of 26 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 26 completed trials
Clinical Trials (61)
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
National Cancer Institute "Cancer Moonshot Biobank"
Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer
IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors
Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery
Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)
Standardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®) in Ovarian Cancer Patients on Adjuvant Chemotherapy
Prospective Cohort Study of Germline Variant Carriers With BRCA1 or BRCA2
Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Feasibility of Saliva and Remote Monitoring of Active Cytomegalovirus (CMV) Infection and Symptoms During Ovarian Cancer Treatment
Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
Body Surface Area-based vs Concentration-based Dosing of Cisplatin for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Women With Advanced Ovarian Cancer
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
NGS-based Germline and Somatic Genetic Test in Ovarian Carcinoma
SCT-001 CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer